following an abbreviated submission:
tenofovir disoproxil (Viread®) is accepted for restricted use within NHS Scotland.
Indication under review: in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infected paediatric and adolescent patients aged 6 to < 12 years, with nucleoside reverse transcriptase inhibitor (NRTI) resistance or toxicities precluding the use of first line agents
SMC restriction: to be prescribed under the supervision of specialists in paediatric infectious diseases.
SMC has previously accepted tenofovir disoproxil for use in combination with other antiretroviral agents in HIV infected patients over 18 years of age experiencing virological failure.
Tenofovir disoproxil is listed in the British National Formulary for Children 2012-2013 for the treatment of HIV infection.
Download detailed advice79KB (PDF)
Medicine details
- Medicine name:
- tenofovir disoproxil (Viread)
- SMC ID:
- 900/13
- Indication:
- In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infected paediatric and adolescent patients aged 6 to < 12 years, with nucleoside reverse transcriptase inhibitor (NRTI) resistance or toxicities precluding the use of first line agents
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 09 September 2013